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A B S T R A C T
The results of the analysis of the treatment of 72 patients with carcinoma of the uterine cervix are presented. Sev-
enty-two patients with Stage IB1 carcinoma of the cervix underwent a radical hysterectomy and pelvic lymphadenec-
tomy. The low-risk group includes the patients without unfavourable prognostic factors that were treated by surgery
alone. The high-risk group included women with pelvic node metastases, clinical tumour size greater than 3.0 cm, depth
of stromal invasion greater than 1/3 of the cervical wall, Grade 3 tumours and the presence of lympho-vascular space in-
volvement. High-risk patients received whole pelvic radiotherapy between two and four weeks following surgery. Thirty-
four patients (47.2%) were in the low-risk group and thirty-eight patients (52.8%) were in the high-risk group. Locore-
gional recurrences were diagnosed in three cases (8.8%) in the surgery group and in four patients (10.5 %) assigned to
postoperative radiotherapy. The incidence of distant metastases was 2.9% in the group treated by surgery alone and 5.3%
in the group treated by surgery and radiotherapy. Overall survival at five years was 91.2% in the low-risk group and
89.5% in the high-risk group of patients. Five-year overall survival, locoregional and distant metastases were similar in
the low-risk and high-risk groups of patients, which emphasizes the value of whole pelvic radiation in patients with one
or more unfavourable prognostic factors after radical surgery in Stage IB1 cervical cancer.
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Introduction
Uterine cervical cancer is the most common gyne-
cological cancer worldwide with a yearly incidence of
500, 000 cases1. It is an important women’s health prob-
lem in developing countries. Risk factors for cervical can-
cer include early onset of sexual activity, multiple sexual
partners, lower socio-economic group and history of sex-
ually transmitted disease. Human papilloma virus has
been implicated as the major causative agent in this dis-
ease. Squamous cell carcinomas account for 80–85% of
cases with adenocarcinoma and adenosquamous carcino-
mas responsible for 15% and 3–5%, respectively2. At the
FIGO Congress in Montreal 1994, the Gynecologic On-
cology Committee made some changes in the staging for
cervical cancer. Stage IB comprises patients with micro-
scopic stromal invasion more than 5.0 mm or with hori-
zontal spread more than 7.0 mm and clinically visible le-
sion confirmed to the cervix. Stage IB1 presents clinical
lesions no greater than 4.0 cm in size and Stage IB2 clini-
cal lesions greater than 4.0 cm in size3. Signs range from
abnormal cervical smear only to a cervix with exophytic
or crater-like type lesions. Symptoms include abnormal
vaginal bleeding, postcoital spotting and vaginal dis-
charge.
The algorithm for the management of Stage IB cervi-
cal cancer includes radical hysterectomy and pelvic lym-
phadenectomy. Patients with lymph node metastases are
treated by postoperative adjuvant pelvic radiation4. Posi-
tive surgical margins, parametrial involvement, tumor
diameter, depth of stromal invasion, tumor grade and
lympho-vascular space involvement are also risk factors
for recurrences. Gynecology Oncology Group (GOG) stu-
dy in 1990, reported clinical tumor size, depth of invasion
of the cervix and lympho-vascular space involvement as
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independent prognostic factors. Patients with negative
lymph nodes in Stage IB cervical cancer have 25% high
risk factors5. Another GOG study in 1999, suggested that
postoperative pelvic radiation reduced the risk of recur-
rences in patients with at least two risk factors: large tu-
mor diameter, more than 1/3 stromal invasion and lym-
pho-vascular space involvement6. Women with Stage IB
or II cervical carcinoma with lymph node metastases
post Wertheim hysterectomy and pelvic lymphadenecto-
my who were given adjuvant radiotherapy treatment had
better survival than those undergoing surgery only in a
multivariate analysis. Patients without pelvic lymph no-
de metastases but with parametrial extension, tumour
size greater than 4 cm, full thickness cervical stromal in-
vasion and DNA index more than 1. 3 had significantly
better five-year recurrence free survival rate if receiving
postoperative radiotherapy7.
In previously published studies patients with cervical
cancer stage IB with unfavourable prognostic factors
were classified in two groups, those who were and those
who were not treated by radiotherapy after surgery. The
five-year survival was significantly higher in those wo-
men who were treated compared to non-treated women
by radiotherapy after surgery. Herein, we evaluate the
whole pelvic radiation in women with vs. those without
unfavourable prognostic factors after surgery of cervical
cancer stage IB1. The recurrence of the disease was the
endpoint of this evaluation.
Subjects, Material and Methods
Seventy-two patients were included into the study
with a mean age 44.2±10.4 years. Initial evaluation in-
cluded medical history, Pap smears and pelvic examina-
tion. When cytology has shown malignant cells in patients
with no visible tumour we made diagnostic conization. In
patients with clinically visible lesions confined to the cer-
vix, diagnosis was confirmed by a directed punch biopsy.
Preoperative evaluation included physical examination,
complete blood count, blood chemistry tests, chest radi-
ography, intravenous pyelogram, cystoscopy and sigmoi-
doscopy. All patients were treated by Wertheim hysterec-
tomy and pelvic lymphadenectomy. When no residual
tumour was found in the radical hysterectomy specimen,
presurgical data from cone biopsies were used. The diag-
noses of squamous cell carcinoma, adenocarcinoma or
adenosquamous cervical cancer were made by a patholo-
gist.
Low-risk group include the patients without unfa-
vourable prognostic factors and they were treated only
by surgery. High-risk group includes women with pelvic
node metastases, clinical tumour size greater than 3.0
cm, depth of stromal invasion greater than 1/3 cervical
wall, Grade 3 tumours and the presence of lympho-vas-
cular space involvement. High-risk patients received ra-
diotherapy between two and four weeks following sur-
gery.
Postoperative radiotherapy was administered to the
pelvic region according to a standardised protocol. The
radiation was delivered by 4 fields’ box technique or by
anteroposterior and posteroanterior parallel-opposed pair
of fields, using linear accelerator or cobalt-60 unit. The
total tumour dose was 40–48 Gy in 20–24 fractions using
2 Gy daily fractions, five days a week.
Patients were evaluated by physical examination, ul-
trasound, Pap smear, blood counts, blood chemistries and
chest radiography every three months for the first two
years, every six months during the next three years and
then annually. Computed tomography scan with contrast
or magnetic resonance imaging of the abdomen and pel-
vis were done at six months and then yearly. Sites of re-
currence were classified as local if detected in the pelvis
or vagina, and distant if detected in extra-pelvic loca-
tions.
The differences were evaluated by Chi-square test
with statistical significance set at p<0.05.
Results
From January 1995, to December 2001, seventy-two
patients with FIGO Stage IB1 cervical cancer were pri-
marily treated by radical surgery. The tumour cell type
was squamous in sixty-one (84.7%) women, adenocarci-
noma in nine (12.5%) and adenosquamous carcinoma in
two (2.8%). Thirty-four patients out of 72 (47.2%) were
low-risk and 38/72 (52.8%) were high-risk patients.
For the low-risk group of patients no further therapy
was applied, while high-risk patients received postopera-
tive whole pelvic radiation. The median interval between
the operation and the first radiotherapy session was 24
days. During radiotherapy the patients were treated with
medication or dietary measures, or both, for related
symptoms.
Local recurrences in the pelvis or vagina were diag-
nosed in three patients (8.8%) in the group treated by
surgery and in four patients (10.5%) treated by postoper-
ative radiotherapy. Distant metastases involving the ab-
domen or lung, or both locations were analyzed. The inci-
dence of distant metastases was 2.9% in the group trea-
ted by surgery alone and 5.3% in the group treated by
surgery and radiotherapy (Table 1). No significant differ-
ences was observed (Chi-square=0,08, p
0.05).
In four patients there were grade 3 or 4 adverse ef-
fects, of which one out of 34 (2.9%) patient was treated
by surgery alone and 3 out of 38 (7.9%) patients were
treated by both surgery and radiotherapy.
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Local 3 (8.8%) 4 (10.5%)
Distant 1 (2.9%) 2 (5.3%)
Total 4 (11.7%) 6 (15.8%)
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Overall survival at five years was 91.2% in the low-
risk group and 89.5% in the high-risk group of patients
(Table 2); almost equal in both groups of patients.
Discussion
The role of postoperative irradiation was evaluated
for patients with Stage IB cervical cancer with tumour-
related risk factors. Three independent prognostic fac-
tors in the GOG study in 1990, clinical tumour size,
depth of tumour invasion and lympho-vascular space in-
volvement made GOG risk score. Score higher than 120
was correlated with 41% recurrence rate5. Sedlis et al.
used a modification of the GOG scoring system and re-
ported a 44% reduction of the risk of recurrences after
adjuvant radiotherapy when a combination of three risk
factors were present compared without postoperative ir-
radiation6. Ayhan et al. reported that tumour size larger
than 4 cm; lympho-vascular space involvement and vagi-
nal involvement were independent prognostic factors in
lymph node negative invasive cervical cancer. Depths of
stromal invasion, parametrial, endometrial and myome-
trial involvement, however, were not independent prog-
nostic factors. Women with one and two or more risk fac-
tors showed lower ratios of pelvic recurrences when
receiving postoperative radiotherapy8. Pieterse et al. be-
fore 1996 received adjuvant radiotherapy for patients
with pelvic node metastases, parametrial invasion or pos-
itive surgical margins. In 1997 they extended the indica-
tion for postoperative irradiation using a modification of
the GOG scoring system. Patients with at least two of the
three risk factors received total pelvic radiotherapy: pa-
thologic tumour size greater than 40 mm, depth of inva-
sion greater than 15 mm and presence of lympho-vascu-
lar space involvement. They found that a significantly
larger percentage of the high-risk group of patients who
did not receive radiotherapy had recurrence of disease
(41% vs. 12%). Differences in five-year cancer specific
survival and five-year disease free survival between the
high-risk groups treated with radiotherapy and without
radiotherapy after radical surgery were statistically sig-
nificant9. In the recent study they found that adjuvant
radiotherapy did not significantly increase the risk of
bladder dysfunction, bowel symptoms, lymphedema and
sexual function after 2-years follow-up10. Scharge et al.
reported that lympho-vascular space involvement is an
important prognostic variable and adjuvant pelvic radia-
tion may decrease the risk of recurrence in this pa-
tients11. GOG study in 2005 suggests that pelvic radio-
therapy after radical surgery significantly reduced the
risk of recurrence and prolongs progression-free survival
in women with Stage IB cervical cancer. Radiation ap-
pears to be particularly beneficial for patients with ade-
nocarcinoma or adenosquamous carcinoma12.
In another our study one hundred and forty eight pa-
tients with Stage IB squamous cell cervical cancer were
primarily treated by radical surgery. Low-risk group in-
cluded 70 patients without unfavourable prognostic fac-
tors that were treated by surgery alone. High-risk group
included 78 women with one or more risk factors: pelvic
node metastases, positive or close surgical margins, clini-
cal tumour size greater than 4.0 cm, stromal invasion
greater than 1/3 cervical wall, Grade 3 tumours and the
presence of lympho-vascular space involvement. High-
risk patients received postoperative whole pelvic radia-
tion. Eleven (15.6%) women in the low-risk group devel-
oped cancer recurrences, nine (12.8%) local, and two
(2.8%) distant. In high-risk patients there were sixteen
(20.5%) cancer recurrences, eleven (14.1%) local and five
(6.4%) distant. Overall survival at five years was 88.6%
in the low-risk group and 84.7% in the high-risk group of
patients13. More of recurrences in the high-risk group
were seen in patients with IB bulky tumours and we re-
duced primarily radical surgery treatment for FIGO
Stage IB1 cervical cancer.
In the recent study the low-risk group includes 34 pa-
tients without unfavourable prognostic factors who were
treated by surgery alone. The high-risk group includes
38 women with one or more risk factors: pelvic node
metastases, tumour size greater than 3.0 cm, stromal in-
vasion greater than 1/3 cervical wall, Grade 3 tumours
and presence of lympho-vascular space involvement. The
high-risk patients received postoperative radiotherapy.
Four (11.7%) women in the low-risk group developed
cancer recurrences, three (8.8%) local, and one (2.9%)
distant. In the high-risk group of patients there were six
(15.8%) cancer recurrences, four (10.5%) local and two
(5.3%) distant. Local relapses were treated by surgery
and patients with distant metastases received chemo-
therapy. Women with squamous cell carcinomas received
cisplatin-based regiments and patients with adenocarci-
noma or adenosquamous type tumours received paclita-
xel-based chemotherapy14. Five-year overall survival rate
in the low-risk group treated by surgery and high-risk,
surgery and radiotherapy treated group was similar, 91.2
and 89.5%, respectively. The adverse effects were not
more expressed in the group of patients treated by adju-
vant total pelvic irradiation after radical surgery. This
emphasizes the value of whole pelvic radiation in pa-
tients with unfavourable prognostic factors in Stage IB1
cervical cancer.
Conclusion
In this study on a relatively small number of patients
with cervical cancer stage IB1 with one or more unfa-
vourable prognostic factors we intended to show the
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FIVE-YEAR SURVIVAL OF PATIENTS ACCORDING TO THE










Low-risk group 34 No 91.2%
High-risk group 38 Yes 89.5%
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value of postoperative adjuvant radiation. Our findings
indicate that the number of local and distal metastasis
were similar to those patients without unfavourable
prognostic factors. The five year survival is also similar
in both groups of patients. The adjuvant total pelvic irra-
diation after radical surgery might represent over treat-
ment in some women but did not generate any side ef-
fects. From all these observations we consider that it is
prove enough to practice whole pelvic radiation in pa-
tients with one or more unfavourable prognostic factors
after radical surgery in Stage IB1 cervical cancer.
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ADJUVANTNA TERAPIJA NAKON RADIKALNE OPERACIJE RAKA VRATA MATERNICE
S A @ E T A K
Prikazani su rezultati analize na{e studije lije~enja 72 bolesnice s rakom vrata maternice. Sedamdeset i dvije paci-
jentice s IB1 stadijem raka vrata maternice podvrgnute su radikalnoj histerektomiji i zdjeli~noj limfadenektomiji. Sku-
pinu niskog rizika ~ine bolesnice bez nepovoljnih prognosti~kih ~imbenika i lije~ene su samo operacijom. Skupinu visokog
rizika tvore `ene s presadnicama u zdjeli~nim limfnim ~vorovima, veli~inom tumora preko 3,0 cm, dubinom invazije
strome ve}om od 1/3, nezrelim tumor ima i nazo~no{}u tumora u limfo-vaskularnim prostorima. Visoko rizi~ne bo-
lesnice primile su zra~enje izvana na zdjelicu izme|u dva i ~etiri tjedna nakon operacije. Trideset ~etiri bolesnice
(47,2%) bile su niskog rizika, a trideset i osam (52,8%) ih je bilo visokog rizika. Lokalni recidiv bolesti je dijagnosticiran
u tri slu~aja (8,8%) u operiranoj skupini i u ~etiri bolesnice (10,5%) koje su odre|ene za radioterapiju. Incidencija udalje-
nih metastaza bila je 2,9% u operiranoj skupini i 5,3% u operiranoj i zra~enoj skupini. Peto-godi{nje pre`ivljenje je bilo
91,2% u skupini bolesnica s niskim rizikom, dok je u skupini bolesnica s visokim rizikom bilo 89,5%. Petogodi{nje
pre`ivljenje, lokalne i udaljene metastaze bile su sli~ne u bolesnica s niskim i visokim rizikom. Ovo isti~e vrijednost
zra~enja zdjelice u bolesnica s jednim ili vi{e nepovoljnih prognosti~kih ~imbenika nakon radikalne operacije IB1 stadija
raka vrata maternice.
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